Registry of Treatment Outcomes in a non-study population of Symptomatic Metastasized Castration Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223 (ROTOR-registry)

Recruiting

• Conditions: Radium-223; prostate cancer

• Registration Number: NL-OMON19873
• Lead Sponsor: etherlands Cancer Institute-Antoni van Leeuwenhoek hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 300

Inclusion Criteria

1.At the physicians discretion

Exclusion Criteria

1.At the physicians discretion

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1.To evaluate the efficacy of Radium-223 treatment in a non-study population by effects on Symptomatic Skeletal Event (SSE)<br /><br>2. Evaluate Radium-223 treatment efficacy by patient reported analgesic use and pain outcome

Secondary Outcome Measures

Name	Time	Method
1. Evaluate Radium-223 treatment efficacy in a non-study population of CRPC patients by clinical parameters.<br /><br>2. Evaluate Radium-223 treatment tolerability in a non-study population of CRPC patients.<br /><br>3. Evaluate the efficacy of the first subsequent therapy by clinical parameters <br /><br>6. Identification of predictive clinical and explorative biomarkers of Radium-223 efficacy